<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Use of menopausal hormone therapy (HT) has been associated with reduced risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>; evidence for its effect on <z:e sem="disease" ids="C0810238" disease_type="Neoplastic Process" abbrv="">other gastrointestinal cancers</z:e> is limited </plain></SENT>
<SENT sid="1" pm="."><plain>We conducted a nested case-control study within a UK cohort, and meta-analyses combining our results with those from published studies </plain></SENT>
<SENT sid="2" pm="."><plain>Our study included women aged 50+ in the UK General Practice Research Database (GPRD): 1,054 with oesophageal, 750 with gastric and 4,708 with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and 5 age- and practice-matched controls per case </plain></SENT>
<SENT sid="3" pm="."><plain>Relative risks (RRs) and 95% confidence intervals (CIs) for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in relation to prospectively-recorded HT prescriptions were estimated by conditional logistic regression </plain></SENT>
<SENT sid="4" pm="."><plain>Women prescribed HT had a reduced risk of <z:e sem="disease" ids="C0546837" disease_type="Neoplastic Process" abbrv="">oesophageal cancer</z:e> (adjusted RR for 1+ vs. no HT prescriptions, 0.68, 95% CI 0.53-0.88; p = 0.004), <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> (0.75, 0.54-1.05; p = 0.1) and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (0.81, 0.73-0.90; p &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>There were no significant differences in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk by HT type, estimated duration of HT use or between past and current users </plain></SENT>
<SENT sid="6" pm="."><plain>In meta-analyses, risks for ever vs. never use of HT were significantly reduced for <z:hpo ids='HP_0000001'>all</z:hpo> three <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (summary RR for <z:e sem="disease" ids="C0546837" disease_type="Neoplastic Process" abbrv="">oesophageal cancer</z:e>, 0.68, 0.55-0.84, p &lt; 0.001; for <z:hpo ids='HP_0012126'>gastric cancer</z:hpo>, 0.78, 0.65-0.94, p = 0.008; for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, 0.84, 0.81-0.88, p &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>In high-income countries, estimated incidence over 5 years of these three <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> combined in women aged 50-64 was 2.9/1,000 in HT users and 3.6/1,000 in never users </plain></SENT>
<SENT sid="8" pm="."><plain>The absolute reduction in risk of these <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in HT users is small compared to the HT-associated increased risk of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
</text></document>